STOCK TITAN

Amneal Announces European Approval of Adcomfo® (Omalizumab), a Biosimilar to XOLAIR®

(Neutral)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Amneal Pharmaceuticals (Nasdaq: AMRX) announced European Commission marketing authorization for Adcomfo, an omalizumab biosimilar to XOLAIR, following earlier UK authorization.

The approval covers add-on treatment for eligible patients with allergic asthma, chronic rhinosinusitis with nasal polyps and chronic spontaneous urticaria. A 600-patient confirmatory study met its primary efficacy endpoint, showing equivalent efficacy to XOLAIR on weekly itch severity change at Week 12, with comparable safety. Kashiv BioSciences developed Adcomfo with Alvotech; Amneal acquired Kashiv in August 2026. ADVANZ PHARMA holds European marketing authorization and regional commercialization rights through its Alvotech partnership. Amneal’s U.S. application remains under FDA review.

Loading...
Loading translation...
3 points · 1 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

0 major · 1 point

How the balance works

Positive

  • Major point600-patient confirmatory study met its primary endpoint, demonstrating equivalent efficacy to XOLAIR at Week 12 with comparable safety.
  • Moderate pointEuropean Commission authorization approves Adcomfo for add-on treatment across three indications in eligible patients.
  • Minor pointUK authorization for Adcomfo was granted in March 2026.

Negative

  • Minor pointU.S. FDA review remains pending for Amneal’s proposed omalizumab biosimilar application.

Key Figures

Study enrollment: 600 patients Primary endpoint assessment: Week 12 Approved presentations: 75 mg, 150 mg and 300 mg pre-filled syringes; 75 mg and 150 mg pre-filled pens
Study enrollment
600 patients
Confirmatory study in patients with chronic spontaneous urticaria
Primary endpoint assessment
Week 12
Equivalent efficacy based on change from baseline in weekly Itch Severity Score
Approved presentations
75 mg, 150 mg and 300 mg pre-filled syringes; 75 mg and 150 mg pre-filled pens
European Commission-authorized Adcomfo presentations

Historical Context

1 past event · Latest: Aug 10
1 event
  1. Aug 10

    Kashiv acquisition

    24h Move
    -1.4%

    Amneal completed Kashiv acquisition, adding a biosimilar R&D, manufacturing and commercialization platform.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

biosimilar, pharmacokinetic
2 terms
biosimilar medical
"a biosimilar to XOLAIR"
A biosimilar is a medicine created to be highly similar to an existing complex drug made from living cells, matching its safety and effectiveness while allowing for small, natural variations. For investors, biosimilars matter because they introduce lower-cost competition when patents end, which can cut prices, shift market share, and change revenue forecasts for companies selling the original drugs, much like a generic version does for simpler chemical medicines.
pharmacokinetic medical
"comparing the pharmacokinetic, pharmacodynamic, safety and immunogenicity"
Pharmacokinetic describes how a drug moves through and leaves the body — how it is absorbed, spread to tissues, broken down and excreted — like tracking a package from pickup to delivery and disposal. For investors, these properties determine effective dose, safety risks, how often a medicine must be taken, and how reliably it works, which in turn influence clinical trial success, regulatory approval chances, production complexity and a drug’s commercial value.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
  • European Commission approval follows UK MHRA authorization of Adcomfo in March 2026
  • U.S. application for proposed biosimilar of XOLAIR® currently under review

BRIDGEWATER, N.J., Nov. 17, 2026 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”) today announced that the European Commission (EC) has granted marketing authorization for Adcomfo® (omalizumab), a biosimilar to XOLAIR®.

Adcomfo, also known as ADL-018/AVT23, was developed by Kashiv BioSciences LLC in collaboration with Alvotech. Amneal acquired Kashiv in August 2026. The European Commission approval follows the positive opinion issued by the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) in September 2026. Separately, Adcomfo received authorization from the UK Medicines and Healthcare products Regulatory Agency (MHRA) in March 2026. Together, these approvals represent important regulatory milestones for the program and expand Adcomfo’s reach across European markets.

“Adcomfo approval by the European Commission is a proud achievement, reflecting years of scientific expertise, dedication and collaboration,” said Andy Boyer, Executive Vice President and Chief Commercial Officer – Affordable Medicines. “This approval further demonstrates the strength of the capabilities supporting our expanding biosimilars portfolio. We see significant opportunity to broaden access to high-quality, affordable biologic medicines while building biosimilars into a durable, long-term growth driver for Amneal.”

Adcomfo is approved as an add-on treatment for severe persistent allergic asthma in eligible patients six years of age and older; as add-on therapy with intranasal corticosteroids for adults with severe chronic rhinosinusitis with nasal polyps (CRSwNP) for whom intranasal corticosteroid therapy does not provide adequate disease control; and as add-on therapy for adults and adolescents 12 years of age and older with chronic spontaneous urticaria (CSU) who have an inadequate response to H1 antihistamine treatment. Adcomfo is approved in 75 mg, 150 mg and 300 mg presentations in pre-filled syringe and 75 mg and 150 mg pre-filled pen configurations.

The approval is supported by a comprehensive analytical and clinical data package demonstrating biosimilarity to reference XOLAIR. The clinical development program included two key studies. The first was a randomized, double-blind, three-arm parallel group, single dose study comparing the pharmacokinetic, pharmacodynamic, safety and immunogenicity of ADL-018 with EU-approved XOLAIR in healthy adults. The second was a randomized, double-blind, multicenter confirmatory study evaluating the efficacy, safety and immunogenicity of ADL-018 compared with XOLAIR in patients with CSU. The study enrolled 600 patients and met its primary efficacy endpoint, demonstrating equivalent efficacy based on change from baseline in weekly Itch Severity Score at Week 12, with comparable safety between treatment groups.

Through the clinical studies conducted in different indications, the most commonly reported adverse reactions were headache, pyrexia, upper abdominal pain, dizziness, arthralgia and injection site reactions. Most of the reactions were mild or moderate in severity.

In Europe, ADVANZ PHARMA holds the marketing authorization and regional commercialization rights for Adcomfo through its partnership with Alvotech.

In the U.S., Amneal’s Biologics License Application (BLA) for its proposed biosimilar to XOLAIR (omalizumab) is currently under review by the U.S. Food and Drug Administration.

About Adcomfo®
Adcomfo (omalizumab) is a biosimilar to XOLAIR, a recombinant DNA-derived humanised monoclonal antibody that selectively binds to human immunoglobulin E (IgE) and prevents binding of IgE to FcɛRI (high-affinity IgE receptor) on basophils and mast cells, thereby reducing the amount of free IgE that is available to trigger the allergic cascade.

Adcomfo® (omalizumab) is associated with potential serious adverse reactions, including a Boxed Warning for anaphylaxis. Anaphylaxis, presenting as bronchospasm, hypotension, syncope, urticaria, and angioedema, may occur after the first dose or after more than one year of treatment and can be life-threatening. In addition, cardiovascular and cerebrovascular events and vasculitis have been identified as potential serious adverse reactions associated with Adcomfo®.

Through the clinical studies conducted in different indications, the most commonly reported adverse reactions were headache, pyrexia, upper abdominal pain, dizziness, arthralgia and injection site reactions. Most of the reactions were mild or moderate in severity.

Omalizumab should be initiated in an appropriate healthcare setting with patient monitoring and readiness to manage anaphylaxis. Patients should be educated on the signs and symptoms of severe allergic reactions and instructed to seek immediate medical attention if they occur. Careful patient selection is recommended for self-administration.

Note: XOLAIR® is a registered trademark of Novartis AG.

About Amneal
Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX), headquartered in Bridgewater, New Jersey, is a diversified, global biopharmaceutical leader focused on expanding access to affordable and innovative medicines. Amneal was founded in 2002 by brothers and co-CEOs Chirag and Chintu Patel, and built on the belief that innovation only matters if it’s accessible. Today, Amneal has a diverse and growing portfolio of approximately 300 complex generic, specialty and biosimilar medicines, delivering more than 160 million prescriptions annually, primarily in the United States. Our Affordable Medicines segment spans retail generics, injectables, and biosimilars. Our Specialty segment provides branded treatments in neurology, including Parkinson’s disease and migraine, and endocrinology. Our AvKARE segment distributes pharmaceuticals and medical products to U.S. federal, retail, and institutional customers. For additional information, please visit amneal.com and follow us on LinkedIn.

Cautionary Statement on Forward-Looking Statements
Certain statements contained herein, regarding matters that are not historical facts, may be forward-looking statements (as defined in the U.S. Private Securities Litigation Reform Act of 1995). Such forward-looking statements include statements regarding management’s intentions, plans, beliefs, expectations, financial results, or forecasts for the future, including among other things: discussions of future operations; expected or estimated operating results and financial performance; and statements regarding our positioning, including our ability to drive sustainable long-term growth, and other non-historical statements. Words such as “plans,” “expects,” “will,” “anticipates,” “estimates,” and similar words, or the negatives thereof, are intended to identify estimates and forward-looking statements. The forward-looking statements contained herein are also subject generally to other risks and uncertainties that are described from time to time in the Company’s filings with the Securities and Exchange Commission, including under Item 1A, “Risk Factors” in the Company’s most recent Annual Report on Form 10-K and in its subsequent reports on Forms 10-Q and 8-K. Forward-looking statements included herein speak only as of the date hereof and we undertake no obligation to revise or update such statements to reflect the occurrence of events or circumstances after the date hereof.

Investor Contact
Anthony DiMeo
VP, Investor Relations
anthony.dimeo@amneal.com

Media Contact
Brandon Skop
Sr. Director, Corporate Communications
brandon.skop@amneal.com


FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Amneal announce about Adcomfo’s European approval?

The European Commission granted marketing authorization for Adcomfo, an omalizumab biosimilar to XOLAIR. ADVANZ PHARMA holds the European marketing authorization and regional commercialization rights through its partnership with Alvotech.

Which patients are eligible for Adcomfo’s approved European indications?

Adcomfo is approved as add-on treatment for severe persistent allergic asthma in eligible patients six years and older. It is also approved with intranasal corticosteroids for adults with severe chronic rhinosinusitis with nasal polyps inadequately controlled by those medicines, and for chronic spontaneous urticaria in adults and adolescents 12 years and older inadequately responsive to H1 antihistamines.

Keep reading